Breaking News | Real-time commentary on the market, with links to key sources.

Thursday, August 28 2008
  • 11:09 AM GlaxoSmithKline (GSK) signs a deal worth up to $820M with Valeant Pharmaceuticals (VRX) for access to the firm's experimental epilepsy treatments. Glaxo has made several deals with smaller partners to expand its pipeline of experimental medicines .